Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

This is some text inside of a div block.
This is some text inside of a div block.

Problem Tech Solves

Tech Brief

Precision Oncology is the key to find better treatments in cancer care, yet there is a mismatch in between patient access and clinical trials to accelerate such R&D while helping patients improve access, equity and possibly clinical outcomes. A recent analysis from the National Cancer Database (NCDB) looking at patients enrolled in clinical trials as their initial course of treatment for 46 cancers from 2004 through 2015 found that out of over 12 million patients, less than 0.1% were enrolled in trials. The analysis also importantly revealed that patients with cancer treated in clinical trials lived longer than those not treated in trials. At the same time, over half of oncology clinical trials have accrual issues or end up closing due to inability to get patients enrolled, showing a data-driven digital engine solution was needed to connect the dots and solve this offer-demand chronic issue in cancer care. https://www.youtube.com/watch?v=a9QA4AfN9oA Most startups have failed to solve this problem by not leveraging network effects, clinical and operational expertise, and relying either on services or technology alone. Massive Bio AI platform and real-time identification, biomarker/genomic assessment, and concierge enrollment has provided a new paradigm to tackle most barriers and provide a sustainable and scalable solution in oncology clinical trials.

Tech Differentiators

We have been able to develop a novel, scalable use case of AI through a platform that is helping patients in real time finding personalized clinical trial options to treat their cancer, while optimizing clinical workflows, advancing precision medicine, novel approaches to oncology research (just-in-time, decentralized clinical trials) and digitally enabled patient centric solutions. The patient level generated data can be leveraged for other equally important use cases such as Real World Evidence, Biomarker Discovery, Synthetic Control Arms, and Research Network Development and Trial Design. We have developed an innovation stack hard to replicate due to combination of strong brand reputation, clinical expertise, AI-enabled technology/deep engineering, patient-level engagement, concierge services, global network/site footprint, CRO and Pharma clients, and highly motivated and mutually complementary founders' team. At this time, Massive Bio has outlived its largest competitors, including IBM Watson and Driver, which is key for consideration and inclusion for the 'Best in Class" category in this competition. The company was founded following cancer diagnoses in the founder’s families, and the realization of the need to use technology to make it affordable and scalable to help as many patients as possible is a passion that drives us to excel and feel excited to make it most successful.


65,000 unique cancer patients have received SYNERGY-AI clinical trial matching reports at the time of submission. We have several case studies. Outcomes and applicability of a deep learning virtual tumor board (DLVTB) in community-dwelling colorectal cancer (CRC) patients. - https://meetings.asco.org/abstracts-presentations/199085 - Stage IV CRC 82.9% were treated by community oncologists. Increase in median Overall Survival of 12 months per patient in comparison with historical cohorts. Additional biomarker testing for 71% of the pts. 63% were eligible for at least one clinical trial. 58% of the trials ≤50 miles of residence. 14% enrolled in the recommended clinical trial, far surpassing the national average (3%). Achieved on average savings of $39,194 per patient which is 35% of the average drug cost per patient. Annals of Oncology: Massive Bio Virtual Tumor Board (VTB) identified clinical trials for 80% of these heavily treated patients, and 50% of patients decided to pursue a clinical trial. Achieved 88% cost reduction compared to standard therapies due to clinical trial enrolment (517,000USD vs 61,000USD). Estimated reported PFS advantage (6.3 months) compared to standard therapy (3.6 months). https://www.annalsofoncology.org/article/S0923-7534(20)34577-4/fulltext SYNERGY-AI Trial Presentation at ASCO: https://massivebio.com/synergy-ai-poster-asco-gastrointestinal-cancers/ Commercial case study: Indication: Solid tumors; refractory tumors, ERBB2 mutated or EGFR exon 18 mutated, no prior targeted therapy. 65 global, 32 US sites. ~400 patients. Coordinated NGS testing for patients to optimize the workup of patients under-genotyped for advanced solid tumors. Results: Total cost reduction: $952,000 Return on investment: 32% Operational simplification: 12% site reduction 42% fewer screenings Gained six months of time

Why Us